Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Insulin Resistance in Primary Hyperparathyroidism (IRIPH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02711059
Recruitment Status : Withdrawn (studien skjuts på framtiden)
First Posted : March 17, 2016
Last Update Posted : September 9, 2020
Sponsor:
Information provided by (Responsible Party):
Inga-Lena Nilsson, Karolinska University Hospital

Brief Summary:
The aims of this study is to analyse if insulin resistance in primary hyperparathyroidism (pHPT) is normalised after parathyroid adenomectomy and if glucose tolerance test may be useful as a diagnostic tool by predicting potential improvement of insulin sensitivity after biochemical cure of pHPT.

Condition or disease Intervention/treatment Phase
Hyperparathyroidism Diabetes Hypercalcemia Procedure: parathyroidectomy Not Applicable

Detailed Description:

To be conducted at the Karolinska University Hospital, Stockholm. Patients with fb-glucos >6.1 and HbA1c without medical treatment will be included after informed consent and randomised to parathyroidectomy (PTX) within three months or not. The groups will be examined 4 ±4 weeks before and 12±2 weeks after PTX, similar for the control group. The number of participants will be estimated by power calculations based on a pilot study including 20 patients.

The test protocol includes glucose load with control of glucose and insulin, (0, 30, 60 and 120 min) together with measurement of markers of oxidative stress and inflammation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Insulin Resistance in Primary Hyperparathyroidism, a Non-classical Manifestation
Study Start Date : October 2015
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : June 2022


Arm Intervention/treatment
Active Comparator: parathyroidectomy
change in insulin resistance
Procedure: parathyroidectomy
surgical treatment of hyperparathyroidism
Other Name: parathyroid adenomectomy

No Intervention: control
the study participant will be examined parallel with the active comparator



Primary Outcome Measures :
  1. glucose tolerance test with estimation of insulin resistance [ Time Frame: 3 months ]
    Homa IR

  2. quality of life - self estimation protocol [ Time Frame: 3 months ]
    EORTC QLQ-C30


Secondary Outcome Measures :
  1. psychological wellbeing [ Time Frame: 3 months ]
    POMS

  2. anxiety, depression [ Time Frame: 6 months ]
    HAD

  3. cognition [ Time Frame: 6 months ]
    MoCA-Test



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • primary hyperparathyroidism and fb-glukos>6,1 and/or HbA1c > 39 mmol/mol

Exclusion Criteria:

  • Treatment with insulin, sulfonylurea or metformin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02711059


Locations
Layout table for location information
Sweden
Karolinska University Hospital
Stockholm, Sweden, SE-17176
Sponsors and Collaborators
Karolinska University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Inga-Lena Nilsson, MD, PhD Karolinska Universitetssjukhuset
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Inga-Lena Nilsson, MD, PhD, consultant surgeon, Karolinska University Hospital
ClinicalTrials.gov Identifier: NCT02711059    
Other Study ID Numbers: KarolinskaUH_pHPT_diabetes
First Posted: March 17, 2016    Key Record Dates
Last Update Posted: September 9, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Inga-Lena Nilsson, Karolinska University Hospital:
hyperparathyroidism
insulin resistance
Additional relevant MeSH terms:
Layout table for MeSH terms
Insulin Resistance
Hypercalcemia
Hyperparathyroidism
Hyperparathyroidism, Primary
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Parathyroid Diseases
Endocrine System Diseases
Calcium Metabolism Disorders
Water-Electrolyte Imbalance
Parathyroid Hormone
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs